share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K：外国发行人报告
SEC announcement ·  04/10 16:03
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the filing of a U.S. patent application for a novel psychedelic-based treatment aimed at eating disorders. The treatment involves the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company, listed on Nasdaq and the Frankfurt Stock Exchange, is positioning itself at the forefront of the weight loss pharmaceutical sector, which is projected to grow significantly due to rising obesity rates worldwide. Clearmind's patent application is part of its broader strategy to develop and commercialize psychedelic-derived therapeutics for major health issues, including alcohol use disorder. The company's intellectual property portfolio currently includes sixteen patent families. The announcement was made on April 10, 2024, and the information was also incorporated by reference into Clearmind's Registration Statements on Form F-3 with the SEC.
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the filing of a U.S. patent application for a novel psychedelic-based treatment aimed at eating disorders. The treatment involves the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company, listed on Nasdaq and the Frankfurt Stock Exchange, is positioning itself at the forefront of the weight loss pharmaceutical sector, which is projected to grow significantly due to rising obesity rates worldwide. Clearmind's patent application is part of its broader strategy to develop and commercialize psychedelic-derived therapeutics for major health issues, including alcohol use disorder. The company's intellectual property portfolio currently includes sixteen patent families. The announcement was made on April 10, 2024, and the information was also incorporated by reference into Clearmind's Registration Statements on Form F-3 with the SEC.
临床阶段的生物技术公司Clearmind Medicine Inc. 宣布申请一项针对饮食失调的新型迷幻药疗法的美国专利。该治疗包括单独使用3-甲基甲卡西酮（3-MMC）或与棕榈酰乙醇胺（PEA）联合使用。该公司在纳斯达克和法兰克福证券交易所上市，正处于减肥制药行业的最前沿，由于全球肥胖率的上升，预计减肥药业将大幅增长。Clearmind的专利申请是其针对主要健康问题（包括酒精使用障碍）开发和商业化迷幻药衍生疗法的更广泛战略的一部分。该公司的知识产权组合目前包括十六个专利家族。该公告于2024年4月10日发布，该信息还以引用方式纳入了Clearmind向美国证券交易委员会提交的F-3表格注册声明。
临床阶段的生物技术公司Clearmind Medicine Inc. 宣布申请一项针对饮食失调的新型迷幻药疗法的美国专利。该治疗包括单独使用3-甲基甲卡西酮（3-MMC）或与棕榈酰乙醇胺（PEA）联合使用。该公司在纳斯达克和法兰克福证券交易所上市，正处于减肥制药行业的最前沿，由于全球肥胖率的上升，预计减肥药业将大幅增长。Clearmind的专利申请是其针对主要健康问题（包括酒精使用障碍）开发和商业化迷幻药衍生疗法的更广泛战略的一部分。该公司的知识产权组合目前包括十六个专利家族。该公告于2024年4月10日发布，该信息还以引用方式纳入了Clearmind向美国证券交易委员会提交的F-3表格注册声明。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息